Investors Buy High Volume of Put Options on Opko Health (OPK)
Opko Health (NYSE:OPK) saw some unusual options trading activity on Monday. Investors bought 5,001 put options on the company, American Banking & Market News reports. This is an increase of approximately 193% compared to the average daily volume of 1,705 put options.
In other Opko Health news, CEO Phillip Md Et Al Frost acquired 20,000 shares of the company’s stock in a transaction that occurred on Friday, June 27th. The shares were purchased at an average price of $8.96 per share, for a total transaction of $179,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
OPK has been the subject of a number of recent research reports. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday, June 25th. They now have a $11.00 price target on the stock, down previously from $11.50. Separately, analysts at TheStreet upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Finally, analysts at TheStreet downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Tuesday, May 13th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Opko Health currently has a consensus rating of “Buy” and a consensus target price of $12.13.
Shares of Opko Health (NYSE:OPK) traded down 2.86% during mid-day trading on Monday, hitting $8.84. The stock had a trading volume of 2,385,264 shares. Opko Health has a 52-week low of $7.13 and a 52-week high of $12.95. The stock’s 50-day moving average is $8.81 and its 200-day moving average is $8.78. The company’s market cap is $3.658 billion.
Opko Health (NYSE:OPK) last released its earnings data on Friday, May 9th. The company reported ($0.11) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.10) by $0.01. The company had revenue of $22.30 million for the quarter, compared to the consensus estimate of $22.77 million. Analysts expect that Opko Health will post $-0.38 EPS for the current fiscal year.
OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.